arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

VERTEX PHARMACEUTICALS INC / MA

VRTX
$496.02 ▲ +11.75 (+2.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
71 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
87
Health
Excellent
Bullish
auto_awesome

Analytical Summary

VERTEX PHARMACEUTICALS INC / MA shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $126.0B
Dividend Yield
Revenue Growth 7.8%
Op. Margin 38.1%
ROIC 4.8%
FCF / Share $5.10
Trailing P/E 122.2x
Price / Book 6.5x
FCF Yield 1.0%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

71-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.99B
↑ +7.8%
Net Income Profit after all expenses
$1.03B
↑ +59.6%
Operating Margin Operating profit as % of sales
38.1%
↑ +0.8% 90th
FCF / Share Free cash flow per share
$5.10
↑ +68.2%
Long-Term Debt Long-term obligations
$105.00M
— 0.0%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
91
Returns
87
Financial Health
97
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 71 quarters